{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By REUTERS", "person": [], "organization": "REUTERS"}, "abstract": "European regulators announce start of safety review of Gilead Sciences\u2019 leukemia drug Zydelig following rise in number of harmful events reports, including deaths, during three clinical trials.", "type_of_material": "News", "word_count": "84", "lead_paragraph": "European regulators have started a review into the safety of Gilead Sciences\u2019 leukemia drug Zydelig over concerns about serious adverse events, including deaths.", "pub_date": "2016-03-12T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Europe Investigates Safety of Gilead Leukemia Drug", "content_kicker": "Business Briefing", "print_headline": "Europe Investigates Safety of Gilead Leukemia Drug"}, "snippet": "European regulators have started a review into the safety of Gilead Sciences\u2019 leukemia drug Zydelig over concerns about serious adverse events, including deaths.", "multimedia": [], "web_url": "http://www.nytimes.com/2016/03/12/business/europe-investigates-safety-of-gilead-leukemia-drug.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Gilead Sciences Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Leukemia", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Europe", "name": "glocations"}, {"rank": "4", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "European Medicines Agency", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Roche Holding AG", "name": "organizations"}], "blog": [], "_id": "56e360f638f0d81b768a68a3", "source": "The New York Times"}